Alterola Biotech Stock Probability of Future Pink Sheet Price Finishing Over 61.59

ABTI Stock  USD 0.01  0  32.76%   
Alterola Biotech's future price is the expected price of Alterola Biotech instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Alterola Biotech performance during a given time horizon utilizing its historical volatility. Check out Alterola Biotech Backtesting, Alterola Biotech Valuation, Alterola Biotech Correlation, Alterola Biotech Hype Analysis, Alterola Biotech Volatility, Alterola Biotech History as well as Alterola Biotech Performance.
  
Please specify Alterola Biotech's target price for which you would like Alterola Biotech odds to be computed.

Alterola Biotech Target Price Odds to finish over 61.59

The tendency of Alterola Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 61.59  or more in 90 days
 0.01 90 days 61.59 
close to zero percent
Based on a normal probability distribution, the odds of Alterola Biotech to move over $ 61.59  or more in 90 days from now is close to zero percent (This Alterola Biotech probability density function shows the probability of Alterola Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Alterola Biotech price to stay between its current price of $ 0.01  and $ 61.59  at the end of the 90-day period is about 6.1 .
Given the investment horizon of 90 days Alterola Biotech has a beta of 0.65. This suggests as returns on the market go up, Alterola Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Alterola Biotech will be expected to be much smaller as well. Moreover Alterola Biotech has an alpha of 1.9822, implying that it can generate a 1.98 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Alterola Biotech Price Density   
       Price  

Predictive Modules for Alterola Biotech

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Alterola Biotech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Alterola Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.0120.54
Details
Intrinsic
Valuation
LowRealHigh
0.000.0120.54
Details
Naive
Forecast
LowNextHigh
0.00010.0120.54
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
00.010.01
Details

Alterola Biotech Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Alterola Biotech is not an exception. The market had few large corrections towards the Alterola Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Alterola Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Alterola Biotech within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.98
β
Beta against Dow Jones0.65
σ
Overall volatility
0
Ir
Information ratio 0.09

Alterola Biotech Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Alterola Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Alterola Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Alterola Biotech is way too risky over 90 days horizon
Alterola Biotech has some characteristics of a very speculative penny stock
Alterola Biotech appears to be risky and price may revert if volatility continues
Alterola Biotech has high likelihood to experience some financial distress in the next 2 years
Alterola Biotech currently holds 251.18 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Alterola Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Alterola Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Alterola Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alterola Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alterola to invest in growth at high rates of return. When we think about Alterola Biotech's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (6.47 M) with profit before overhead, payroll, taxes, and interest of 0.

Alterola Biotech Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Alterola Pink Sheet often depends not only on the future outlook of the current and potential Alterola Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Alterola Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding770 M
Shares Float163.6 M

Alterola Biotech Technical Analysis

Alterola Biotech's future price can be derived by breaking down and analyzing its technical indicators over time. Alterola Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Alterola Biotech. In general, you should focus on analyzing Alterola Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

Alterola Biotech Predictive Forecast Models

Alterola Biotech's time-series forecasting models is one of many Alterola Biotech's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Alterola Biotech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about Alterola Biotech

Checking the ongoing alerts about Alterola Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Alterola Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Alterola Biotech is way too risky over 90 days horizon
Alterola Biotech has some characteristics of a very speculative penny stock
Alterola Biotech appears to be risky and price may revert if volatility continues
Alterola Biotech has high likelihood to experience some financial distress in the next 2 years
Alterola Biotech currently holds 251.18 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Alterola Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Alterola Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Alterola Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alterola Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alterola to invest in growth at high rates of return. When we think about Alterola Biotech's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (6.47 M) with profit before overhead, payroll, taxes, and interest of 0.

Other Information on Investing in Alterola Pink Sheet

Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.